Publications '19 - Present

91. Pützer, B. M., & Sabapathy, K. (2022). Editorial: Multidisciplinary Approaches in Exploring Cancer Heterogeneity, TME and Therapy Resistance: Perspectives for Systems Medicine. Frontiers in cell and developmental biology, 10, 842596.

90. Hwang, L. A., Phang, B. H., Liew, O. W., Iqbal, J., Koh, X. H., Koh, X. Y., Othman, R., Xue, Y., Richards, A. M., Lane, D. P., & Sabapathy, K. (2021). Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine. Cell reports, 36(6), 109498.

89. Bhatta, B., Luz, I., Krueger, C., Teo, F. X., Lane, D. P., Sabapathy, K., & Cooks, T. (2021). Cancer Cells Shuttle Extracellular Vesicles Containing Oncogenic Mutant p53 Proteins to the Tumor Microenvironment. Cancers, 13(12), 2985.

88. Li, D., Dulloo, I., & Sabapathy, K. (2021). Correction to: context-dependent AMPK activation distinctly regulates TAp73 stability and transcriptional activity. Signal transduction and targeted therapy, 6(1), 163.

87. Sabapathy K. (2021). Corrigendum: The Contrived Mutant p53 Oncogene - Beyond Loss of Functions. Frontiers in oncology, 11, 665504.

86. Xie, M., Chia, R. H., Li, D., Teo, F. X., Krueger, C., & Sabapathy, K. (2021). Functional interaction between macrophages and hepatocytes dictate the outcome of liver fibrosis. Life Science Alliance, 4(4), e202000803.

85. Tan, C. T., Chang, H. C., Zhou, Q., Yu, C., Fu, N. Y., Sabapathy, K., & Yu, V. C. (2021). MOAP-1-mediated dissociation of p62/SQSTM1 bodies releases Keap1 and suppresses Nrf2 signaling. EMBO Reports, 22(1), e50854.

84. Gatellier, L., Matsuda, T., Sabapathy, K., Dai, M., Dewi, L., Huong, T. T., Kardinah, K., Thuan, T. V., Park, J. B., He, J., Nansalmaa, E., Luvsandorj, B., Hwang, W., Sengar, M., Pramesh, C. S., & Suzuki, T. (2020). An Asian Body to Tackle Cancers in Asia - The Asian National Cancer Centers Alliance. Asian Pacific Journal of Cancer Prevention, 21(5), 1207–1212.

83. Wang, C., Teo, C. R., & Sabapathy, K. (2020). p53-Related Transcription Targets of TAp73 in Cancer Cells-Bona Fide or Distorted Reality?. International Journal of Molecular Sciences, 21(4), 1346.

82. Kumar, R., & Sabapathy, K. (2019). RNF4-A Paradigm for SUMOylation-Mediated Ubiquitination. Proteomics, 19(21-22), e1900185.

81. Ubby, I., Krueger, C., Rosato, R., Qian, W., Chang, J., & Sabapathy, K. (2019). Cancer therapeutic targeting using mutant-p53-specific siRNAs. Oncogene, 38(18), 3415–3427.

80. Sabapathy, K., & Lane, D. P. (2019). Understanding p53 functions through p53 antibodies. Journal of Molecular Cell Biology, 11(4), 317–329.